Publication:

Study of plasma adiponectin level in patients with metabolic syndrome

Background The metabolic syndrome (MS) is a cluster of interrelated common clinical disorders, including hypertension, insulin resistance, glucose intolerance and dyslipidaemia, in addition to obesity. Central obesity accompanied by insulin resistance is a keyfactor in the development of metabolic syndrome (MS) and future macro vascular complications. Adiponectin is the most abundant peptide secreted by adipocytes, being a key component in the interrelationship between adiposity, insulin resistance and inflammation. Hypoadiponectimia has already been associated with the risk of the MS in several populations. Plasma adiponectin level was measured in the current study to clarify its role as a biomarker for metabolic syndrome (MS).

Methods This study was conducted on 40 MS patients (Group I) compared with 20 age and sex matched healthy volunteers (Group II). All patients and controls were subjected to full medical history, clinical examination and laboratory investigations in addition to plasma adiponectin level.

Results Plasma adiponectin levels were significantly lower in subjects with MS when compared with subjects with no diagnosis of MS. There was significant negative correlation between plasma adiponectin and age, waist circumference, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood sugar, insulin resistance, serum insulin, and triglycerides. Also there was significant positive correlation between plasma adiponectin and HDL.

Conclusion We conclude that adiponectin levels could help as a biomarker for cases of MS.